DNB Markets acted as Joint Bookrunner in connection with Wilson Therapeutics' (Nasdaq Stockholm; WTX) SEK 244 million private placement.
The private placement launched after close of trading Thursday 7 December and was conducted as an accelerated book-building. Strong demand was generated from reputable institutions and sector specialist funds, both internationally and in Sweden.
Wilson Therapeutics is a biopharmaceutical company that develops novel therapies for patients with rare copper-mediated disorders. Its lead product, WTX101, is a first-in-class drug with potential to address the significant unmet medical needs in Wilson Disease.